1-3 of 3
William N. Harwin, MD
Close
Sort by
Journal Articles

Relationship Between Lenalidomide Dose Modification and Duration Of Treatment In Newly Diagnosed Multiple Myeloma Patients

Kathy Lang, PhD, Gary Binder, MBA, Iris Lin, PhD, Dejan Milentijevic, PhD, Huan Huang, PhD, Yasir Nagarwala, MD, William N. Harwin, MD
Journal: Blood
Blood (2013) 122 (21): 2944.
https://doi.org/10.1182/blood.V122.21.2944.2944
Published: 2013
Journal Articles

Phase II Trial of Ofatumumab (OFA) for Older Patients and Patients Who Refuse Fludarabine-Based Regimens with Previously Untreated Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Ian W. Flinn, MD, PhD, William N. Harwin, MD, Patrick Ward, MD, PhD, Habib H. Doss, MD, Steven W. Papish, MD, John D. Hainsworth, MD, Jesus G. Berdeja, MD, John C. Byrd, MD
Journal: Blood
Blood (2012) 120 (21): 719.
https://doi.org/10.1182/blood.V120.21.719.719
Published: 2012
Journal Articles

A Phase II Trial of Ofatumumab for Older Patients and Patients Who Refuse Fludarabine-Based Regimens with Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma,

Ian W. Flinn, MD, PhD, William N. Harwin, MD, Inés M. Macias-Pérez, PhD, Patrick S. Tucker, MS, David M. Waterhouse, MD, Steven W. Papish, MD, Jeffrey A. Jones, MD, MPH, John D. Hainsworth, MD, John C. Byrd, MD
Journal: Blood
Blood (2011) 118 (21): 3912.
https://doi.org/10.1182/blood.V118.21.3912.3912
Published: 2011